# Sun Pharma share price today (Sun Pharmaceutical Industries Ltd, NSE: SUNPHARMA)

> Sun Pharma share price today: ₹1,769.90 at the NSE close on 3 November 2026, up 4.7% in a year. Sun Pharmaceutical Industries (NSE: SUNPHARMA) is worth ₹4,24,587 crore, trades at a P/E of 34.5 and has closed between ₹1,610.10 and ₹1,990.50 over the past 52 weeks. > Sun Pharmaceutical Industries Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SUNPHARMA · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹1,769.90 (+4.7% in a year)
- P/E: 34.5× (higher than 66% of the last 11 years)
- Revenue (Sep 2026): ₹16,199 Cr (+11.9% on a year ago)
- Profit (Sep 2026): ₹1,995 Cr (−36.2% on a year ago)
- Operating margin: 29.0% (−2.0 points on a year ago)
- ROCE: 21%, FY26
- ROIC: 18.4%, against a 12.0% cost of capital: +6.4 points

The main question: domestic institutions moved +3.8 percentage points over 8 quarters while the business went the other way. ## What is the Sun Pharma share price today? Sun Pharmaceutical Industries Ltd's share price was ₹1,769.90 at the close on 3 November 2026. It has been rising for 27 weeks. That is 2.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,610 and ₹1,991, and at that close it sat 42% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running. Over the last 11 years the share price moved +104% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sun Pharma this quarter? Three changes stood out: foreign funds (FIIs) cut their stake for 7 quarters in a row, indian funds and insurers (DIIs) raised their stake for 7 quarters in a row and revenue up on a year earlier for 12 quarters in a row (every quarter we can compare). 1. Foreign funds (FIIs) cut their stake for 7 quarters in a row From 18% to 14.4% of the company by the September 2026 quarter. 2. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row From 18.4% to 22.3% of the company by the September 2026 quarter. 3. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹16,199 crore, +11.9% on a year earlier. Why: Revenue rose because India sales grew on more volume and a wider prescriber base, more than offsetting weaker US sales. Next results: check whether Ilumya US prescriptions recover after the slowdown, since management expects its actions and a new use to bring back usual growth. From the earnings call on 30 Oct 2026. ## What are Sun Pharma's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sun Pharma reported revenue of ₹16,199 crore, up 11.9% from ₹14,478 crore a year earlier, and a profit of ₹1,995 crore, down 36.2% from ₹3,125 crore. ### Sun Pharma results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹16,199 crore | ₹14,478 crore | +11.9% |
| Profit | ₹1,995 crore | ₹3,125 crore | −36.2% |
| Earnings per share | ₹8.29 | ₹13.00 | −36.2% |
| Operating margin | 29.0% | 31.0% | −2.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Sun Pharma's management discussed these results on a call held on 30 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Sun Pharma share price history? Sun Pharma closed at ₹1,769.90 on 3 November 2026, up 4.7% from ₹1,690.70 a year earlier (31 October 2025) and up 122.5% over five years. Its highest weekly close since March 2016 was ₹1,990.50 on 31 July 2026. ### Sun Pharma share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,748.00 | +1.3% |
| 1 month ago · 1 Oct 2026 | ₹1,801.00 | −1.7% |
| 6 months ago · 30 Apr 2026 | ₹1,808.30 | −2.1% |
| 1 year ago · 31 Oct 2025 | ₹1,690.70 | +4.7% |
| 3 years ago · 3 Nov 2023 | ₹1,141.10 | +55.1% |
| 5 years ago · 4 Nov 2021 | ₹795.45 | +122.5% |
| 10 years ago · 4 Nov 2016 | ₹651.50 | +171.7% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹868.20 | +103.9% |
| Highest weekly close since March 2016, also the 52-week high · 31 Jul 2026 | ₹1,990.50 | −11.1% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹338.25 | +423.3% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹1,610.10 | +9.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Sun Pharma? 3 Nov 2026: Sun Pharma closed at ₹1,769.90, up 1.3% on the week and down 1.7% on the month. 30 Oct 2026: Sun Pharma held its results call for July to September 2026. Management guided: FY27 sales growth high single-digit reiterated. ### Earlier

- Results for July to September 2026: Revenue up 11.9% and profit down 36.2% on a year earlier. - 7 Jul 2026: ex-date for a dividend of ₹5 a share. - 5 Feb 2026: ex-date for an interim dividend of ₹11 a share. ## What dividend does Sun Pharma pay? Sun Pharma paid ₹16 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 0.90% at the ₹1,769.90 close on 3 November 2026. The last was a dividend of ₹5 a share, ex-date 7 July 2026. ### Sun Pharma dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 7 Jul 2026 | ₹5 | Dividend | same day |
| 5 Feb 2026 | ₹11 | Interim | same day |
| 7 Jul 2025 | ₹5.50 | Dividend | same day |
| 6 Feb 2025 | ₹10.50 | Interim | same day |
| 12 Jul 2024 | ₹5 | Dividend | same day |
| 9 Feb 2024 | ₹8.50 | Interim | same day |
| 28 Jul 2023 | ₹4 | Dividend | same day |
| 8 Feb 2023 | ₹7.50 | Interim | same day |
| 19 Aug 2022 | ₹3 | Dividend | 22 Aug 2022 |
| 9 Feb 2022 | ₹7 | Interim | 10 Feb 2022 |
| 23 Aug 2021 | ₹2 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Sun Pharmaceutical Industries Ltd paid out 33% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Sun Pharma management say on the latest results call? On the call for July to September 2026, held on 30 October 2026, Sun Pharma's management guided: FY27 sales growth high single-digit reiterated. > “It is really a variety of things. I think there is a bit of market saturation, but frankly, part of it is execution as well.”
> Richard Asfalg, on the call for July to September 2026

### What management guided

- FY27 R&D at 6-7% of sales with sharp second-half ramp. - Organon close in January to March 2027 to early 2027 subject to remaining conditions. - Psoriatic arthritis soft launch in November with full launch in following months. - Ilumya return to typical growth over next few quarters on interventions plus new indication. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/2757-30-Oct-2026.pdf). (From the call for July to September 2026, 30 October 2026.)

## What is the future of Sun Pharma? What is changing in the business? What is changing at Sun Pharma, from the latest results and calls: global innovative specialty portfolio scale, india domestic market leadership & volume outperformance and generic semaglutide commercial scaling. - Global Innovative Specialty Portfolio Scale. Innovative medicines reached US$351 million in April to June 2026, up 12.8% year-on-year and 21.9% of consolidated sales. ⚠ estimate
- India Domestic Market Leadership & Volume Outperformance. India formulations grew 16.0% year-on-year to ₹54,749 million with 8.5% market share. ⚠ estimate
- Generic Semaglutide Commercial Scaling. Sun became the number-two generic Semaglutide injectable player in India and remains the only Indian provider of an auto-injector. ⚠ estimate
- Organon Global Scale & Platform Transformation. The proposed Organon transaction would create a US$12.4 billion revenue entity and goal US$350 million of cost synergies. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What could change the Sun Pharma story? What are the risks? Price competition or device-component constraints prevent commercial uptake. ### Each change stops working if

- Generic Semaglutide Commercial Scaling: Price competition or device-component constraints prevent commercial uptake. - Organon Global Scale & Platform Transformation: Closing fails, synergy realization is delayed, or established-brand revenue declines faster than planned. ### The main risks

- Post-Acquisition Balance Sheet Leverage: Net debt to operating profit would rise to 2.3x post-close, with deleveraging dependent on combined free cash flow. ✓ fact
- US Generic Revenue Erosion & Site Compliance Delays: US sales declined 9.7% year-on-year in April to June 2026 as generic erosion outweighed innovative-medicines growth. ✓ fact
- Effective Tax Rate Normalization: The effective tax rate has normalized toward 25%, creating a continuing profit headwind versus historical low-tax periods. ✓ fact
- Transaction Closing Uncertainty & Shareholder Approval: Organon closing remains subject to shareholder and regulatory approvals. ✓ fact

(Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Sun Pharma's next results? When Sun Pharma reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ilumya US prescription trend over next few quarters - check whether interventions plus new indication restore typical growth. - What to check (from the call)
- Ilumya US prescription trend over next few quarters - check whether interventions plus new indication restore typical growth. - Second-half research spend pace - check catch-up toward full-year range on trial recruitment and infrastructure. - Organon remaining approvals and Day-1 readiness - check close tracking communicated window without slippage. - Lerodalcibep country pricing progress and first commercial launch signals - check pre-launch to launch conversion. ## Which stock lists is Sun Pharma on? Sun Pharma is on 2 of our India lists: Nifty 50 companies and Pharma stocks. - [Nifty 50 companies](https://www.sectoralpha.in/nifty-50-stocks-list)
- [Pharma stocks Market value (₹ crore): 424682.511109861](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Sun Pharma profitable? Sun Pharmaceutical Industries Ltd earned ₹1,995 Cr of net profit in the Sep 2026 quarter, −36.2% on the same quarter a year earlier. Full-year FY26 profit was ₹11,509 Cr. Over 10 years profit has grown 7.4% a year on average. That is 12.3% of the quarter's revenue. The same quarter a year earlier earned ₹3,125 Cr. For the full year, FY26 profit was ₹11,509 Cr (+5.0% on the year before). Why profit moved: revenue changed +11.9% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +8.1% and revenue +12.2%. Profit is growing slower than sales: rising costs are taking part of the growth. FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported. FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much revenue does Sun Pharma make, and is it growing? Sun Pharmaceutical Industries Ltd reported ₹16,199 Cr of revenue in the Sep 2026 quarter, +11.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.5% a year on average. The last full year, FY26, came in at ₹58,462 Cr. Why this happened. India formulations represented 36.1% of consolidated sales in Q1 FY27. PharmaTrac growth was 30.4%; management stated volume plus new products contributed the majority and five products were launched. The last four reported quarters add to ₹61,632 Cr. FY26 revenue was ₹58,462 Cr, +11.2% on the year before. Recent pace: the last four quarters grew +12.2% on average, against 7.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.1%, against +10.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +4.8%, against −0.6% a year (accelerating). FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported. FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Sun Pharma keep? Sun Pharmaceutical Industries Ltd's operating margin was 29.0% in the Sep 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 21.0% and 44.0%. The latest quarter is within that range. Why this happened. Organon contributes US$6.2 billion revenue, stable 30% EBITDA margin and approximately US$1 billion annual free cash flow before financing. Cost synergies are planned across procurement, G&A and supply chain over two to four years, subject to closing and execution. Why the margin moved: operating margin changed −2.0 percentage points on the year while gross margin changed +1.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged. FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported. FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## Is Sun Pharma's profit turning into cash? Over the last 3 years, 120% of Sun Pharmaceutical Industries Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹12,419 Cr of operating cash against ₹11,509 Cr of profit. After ₹9,582 Cr of spending on assets, ₹2,837 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 120% of profit came in as cash: the cash cycle got 82 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 1.8× depreciation over three years. The next section checks what that spending is building. ## Where does Sun Pharma's cash go? Sun Pharmaceutical Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 228 days in FY26, down from 310 days in FY21. It spent ₹14,906 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 363 days on average. Why this happened. The portfolio grew from US$400 million in 2021 to US$700 million currently. Commercial execution depends on reimbursement, interchangeability and pricing dynamics. At FY26 sales of ₹58,462 Cr, each day of that cycle ties up about ₹160 Cr, so roughly ₹36,519 Cr is tied up in the business at any time. FY26: customers took 97 days to pay and stock sat for 363 days, about 11.9 months of sales sitting as stock, for a full cycle of 228 days, shorter than FY21's 310. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 363 days. Customers pay about 97 days after that. Suppliers are paid at 232 days. Together that makes the 228-day cycle. Spending on assets: ₹14,906 Cr over the last 3 years, against ₹8,070 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3,052 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sun Pharma's P/E ratio, and how does it compare with its own history? Sun Pharmaceutical Industries Ltd's P/E is 34.5×, in the middle of its own history: higher than 66% of past readings. Its usual P/E (the middle reading) is 30.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹45.70. Why the multiple is where it is: over the past year earnings per share moved +5.0% while the price moved +4.7%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +17.3% a year; about +12.4% a year came from earnings growth and about +4.9 percentage points from the multiple (the market paying more); over 10 years the price moved +10.5% a year; about +3.9% a year came from earnings growth and about +6.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Sun Pharma share price assume? Worked out from its price on 26 August 2026, Sun Pharmaceutical Industries Ltd's share price assumed profit growth of about 21.1% a year. Over the past 10 years its profit actually grew 7.4% a year. Today its P/E is 34.5×, higher than 66% of its own last 11 years. This is a one-day reading, taken on 26 August 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Sun Pharma business getting better or worse? Sun Pharmaceutical Industries Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 17.9%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the Sun Pharma story, and has it been checked? Sun Pharmaceutical Industries Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: MID EXPANSION AT PEAK MARGIN. Our read, 22 August 2026. What is proven. What is not proven yet. What would change our mind. The test written in advance. Measured by: the thesis as written as stated by the next result. The test written in advance. Post-Acquisition Balance Sheet Leverage. Measured by: Post-Acquisition Balance Sheet Leverage Combined entity free cash flow and net debt in the first two quarters after closing. by the next result. The test written in advance. Management Guidance Credibility & Strategy Contradictions. Measured by: Management Guidance Credibility & Strategy Contradictions Integration-office disclosure and consistent post-close capital-allocation communication. by the next result. What the company does. India formulations grew 16.0% year-on-year in Q1 FY27, while innovative medicines delivered US$351 million of sales and US generics declined 9.7% year-on-year. The Organon transaction adds scale, biosimilars and women's health but would raise net debt to EBITDA to 2.3x at close and requires execution against a flat established-brands base. What the surface reading misses. What the surface reading misses. The surface reading is: ROCE of 20.5% exceeds the stated ROE of 16.0%. The research reads it further: These returns are standalone figures; proposed Organon leverage and goodwill could alter post-close return metrics. Lever 15 · Market-share gains: building. India formulations grew 16.0% year-on-year to Rs 54,749 million with 8.5% market share. What proves it keeps working: India Domestic Market Leadership & Volume Outperformance. It stops working if India market-share losses or growth below the industry rate persist for multiple quarters. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Sun Pharma management deliver what it promised? What Sun Pharmaceutical Industries Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Ilumya Outlook Reversed · 30 October 2026. In Jul 2026, management characterized US innovative medicines as expected to continue healthy growth and specifically said Ilumya was doing well. In Oct 2026, management instead identified an Ilumya slowdown as a key driver of slower global innovative-medicine growth and later attributed it partly to market saturation and execution, a material change in outlook that merits explanation. Conflicting Organon Closing Fiscal Year · 30 October 2026. In Jul 2026, management stated that the Organon acquisition would be completed in Q4 FY27, and the Oct 2026 prepared remarks repeated that timeline. However, the Oct 2026 Q&A referred to closing in Q4 FY25 when discussing the final estimate of acquisition-related costs, creating a material fiscal-period conflict for modeling transaction timing and exceptional expenses. M&A Strategy Pivot - From Disciplined Tuck-ins to Transformative Mega-Deal · 27 April 2026. In the Jan 2026 call, Dilip Shanghvi explicitly described Sun's M&A posture as pursuing tuck-ins or smaller acquisitions in emerging markets and stressed that acquisitions would only be considered if manageable without diluting focus on organic growth. Just three months later in the Apr 2026 call, Sun announced the acquisition of Organon at an enterprise value of $11.75 billion - a company of comparable scale to Sun itself - while accepting 2.3x net debt to EBITDA, a complete departure from the stated approach with no prior communication of any strategy pivot of this magnitude. Dividend Policy - From Active Increase to Declared Uncertainty · 27 April 2026. In the Jan 2026 call, the Board declared an increased interim dividend of Rs.11 per share for FY26, up from Rs.10.5 the prior year, projecting a clear upward dividend trajectory for shareholders. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Sun Pharma earn on its capital? Sun Pharmaceutical Industries Ltd earned a ROCE of 21% in FY26. That is up from a low of 10% in FY18. Its return on capital used (ROIC) is 6.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.7% net margin and 0.54× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 19.7% net margin × 0.54× asset turnover × 1.30× leverage (assets divided by equity) ≈ 13.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 18.4% − 12.0% = +6.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 18.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 20.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Sun Pharma have too much debt? Sun Pharmaceutical Industries Ltd has total debt of ₹3,241 Cr against shareholder equity of ₹89,564 Cr as of Sep 2026, so its debt is 0.04× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.06 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sun Pharma shareholding pattern? Domestic institutions raised their stake in Sun Pharmaceutical Industries Ltd by 3.8 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 22.3% of the company. Foreign institutions moved −3.7 points over the same period, to 14.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +3.8 points over 8 quarters, to 22.3%; Foreign institutions: −3.7 points over 8 quarters, to 14.4%; Promoters: −1.8 points over 8 quarters, to 52.7%. Why the owners changed: foreign institutions moved −3.7 points and domestic institutions +3.8 points over 8 quarters, while promoters moved −1.8 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Sun Pharma from balance-sheet trouble? For Sun Pharmaceutical Industries Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sun Pharma rank in its industry? 39.4 out of 100, rank 33 of 44 in Pharma - Formulators, with 100% of the evidence available. Sun Pharmaceutical Industries Ltd scores 39.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 33. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 12.5 + 17.2 + 4.9 + 4.8 = 39.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sun Pharma compared with? Sun Pharma ranks 33 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 39.4 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. Sun Pharmaceutical Industries Ltd this page SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 12.1% · Profit 4.8% · Operating margin change -2 points · 100% evidence Capital efficiency 17.2/25 · ROCE 20.5% · Operating margin 29% · 100% evidence Valuation 4.9/20 · P/E 34.7× · PEG 4.21 · 100% evidence Relative strength 4.8/20 · Lead over its industry -17.4% · Lead over NIFTY 500 3.8% · 1 year 5.1% · 100% evidence · 2 of 12 weeks ahead Exact sum: 12.5 + 17.2 + 4.9 + 4.8 = 39.4 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Sun Pharma in size? Sun Pharma is the largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Torrent Pharmaceuticals, Zydus Lifesciences, Dr Reddys Laboratories, Cipla, Mankind Pharma and Aurobindo Pharma. ### Pharma - Formulators companies close in size

1. Sun Pharmaceutical Industries Ltd ₹4,26,530 crore
2. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) ₹1,75,479 crore
3. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ₹1,24,239 crore
4. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) ₹1,12,849 crore
5. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) ₹1,11,397 crore
6. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) ₹1,02,964 crore
7. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) ₹96,744 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [National Stock Exchange Of India Ltd](https://www.sectoralpha.in/stocks/national-stock-exchange-of-india-ltd) ₹4,41,070 crore
2. [Hindustan Unilever Ltd](https://www.sectoralpha.in/stocks/hindustan-unilever-ltd) ₹4,38,105 crore · FMCG - Personal Care
3. Sun Pharmaceutical Industries Ltd ₹4,26,530 crore
4. [Adani Ports & Special Economic Zone Ltd](https://www.sectoralpha.in/stocks/adani-ports-special-economic-zone-ltd) ₹4,26,232 crore · Marine Port & Services
5. [Titan Company Ltd](https://www.sectoralpha.in/stocks/titan-company-ltd) ₹3,93,866 crore · Diamond, Gems & Jewellery

## What else do people ask about Sun Pharma? ### What is Sun Pharma's share price today? Sun Pharmaceutical Industries Ltd's share price is ₹1,769.90, +4.7% over the past year. The whole company is worth ₹4,24,587 Cr on the market. In the last 52 weeks it traded between ₹1,610 to ₹1,991; today it is 42% of the way up from the low, 2.5% below its 200-day average (as of 3 November 2026). ### What were Sun Pharma's latest quarterly results? Sun Pharmaceutical Industries Ltd reported revenue of ₹16,199 Cr and net profit of ₹1,995 Cr for the Sep 2026 quarter. Revenue rose 11.9% and profit fell 36.2% compared with a year earlier. Earnings per share were ₹8.29. The operating margin was 29.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Sun Pharma's market cap? Sun Pharmaceutical Industries Ltd's market capitalisation is ₹4,24,587 Cr at a share price of ₹1,769.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sun Pharma performing? Sun Pharmaceutical Industries Ltd's share price has been rising for 27 weeks. In its latest quarter, revenue rose 11.9% and profit fell 36.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 5 weeks running (as of 3 November 2026). ### Will Sun Pharma's share price go up? This page does not forecast Sun Pharmaceutical Industries Ltd's share price. What it shows instead: the share price is ₹1,769.90, and it has been rising for 27 weeks. Its P/E of 34.5× is higher than 66% of its own last 11 years (as of 3 November 2026). ### Does Sun Pharma have too much debt? No, Sun Pharmaceutical Industries Ltd has little debt: its debt is 0.06× its equity, and its operating profit is 49 times its interest bill. FY26 borrowings were ₹4,627 Cr against equity of ₹83,570 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Sun Pharma in its business cycle? Sun Pharmaceutical Industries Ltd's FY26 operating margin was 28.0%, against a 13-year range of 21.0% to 44.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 29.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sun Pharma story? The main question: domestic institutions moved +3.8 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sun Pharma a stock worth studying right now? What the numbers show: Sun Pharmaceutical Industries Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Sun Pharma share price forecast for 2026? What management itself guided: FY27 sales growth high single-digit reiterated. What is changing at Sun Pharma, from the latest results and calls: global innovative specialty portfolio scale, india domestic market leadership & volume outperformance and generic semaglutide commercial scaling. What would change the story: Price competition or device-component constraints prevent commercial uptake. ## Lists

- Nifty 50 companies: https://www.sectoralpha.in/nifty-50-stocks-list
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.